Keyword: New Enterprise Associates

Galera will use the proceeds to start a phase 3 study of GC4419, which seems to prevent severe oral mucositis in patients with head and neck cancers.

Roivant Sciences named NEA partner Frank Torti as Vant investment chair to serve as one of two appointed representatives at its subsidiaries.

The cash sets Intact up to advance a clinical development program designed to generate data to support FDA approval of the Tack Endovascular System.

The device is designed to enable the remote monitoring of heart failure patients and thereby improve outcomes.

Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.

The series C sets Amplyx up to take its lead broad-spectrum antifungal candidate into phase 2 later this year.

Canaan will continuw the strategy that has delivered it paydays as companies including J&J and Teva have snapped up pieces of its portfolio.

Senseonics is set to raise $41 million to support commercialization of implantable continuous glucose monitoring system Eversense.

Intrinsic Therapeutics raised $49 million for its implant that addresses challenges in spinal surgery to remove a herniated disc.

Advanced Cardiac Therapeutics raised $45 million in equity, which will drive global clinical development for its next-generation ablation catheter.